期刊文献+

人凝血因子Ⅷ几种冻干保护剂的比较 被引量:7

在线阅读 下载PDF
导出
摘要 目的探讨不同冻干保护剂对人凝血因子Ⅷ(FⅧ)制品在冻干及干热(100℃,30min)过程中的作用。方法同批次人FⅧ样品在相同冻干条件及一定保护剂(0.3%甘氨酸、1.5%蔗糖、1.0%白蛋白)组成的基础上,改变甘氨酸、蔗糖、白蛋白、木糖醇和精氨酸5种冻干保护剂的含量或种类,组合成6组配方,对不同配方冻干及干热后FⅧ制品外观、复溶后澄清度及FⅧ活性等进行分析比较。结果Ⅰ组(3%甘氨酸):冻干和干热后制品成形最好,但复溶后均有少量絮状物;Ⅱ组(5%蔗糖):冻干和干热后制品均萎缩,冻干过程部分制品水份未抽干,冻干后澄清度较好,干热后部分有少量絮状物;Ⅲ组(2%白蛋白):冻干和干热后制品成形较好,但复溶后均有絮状物;Ⅳ组(5%木糖醇):冻干后制品萎缩,复溶后澄清度最好,干热后膨胀,复溶后有大量絮状物;Ⅴ组(1.2%精氨酸):冻干和干热后制品萎缩,但复溶后澄清度均较好;Ⅵ组(5%木糖醇+1.2%精氨酸):冻干后制品膨胀,复溶后澄清度较好,干热后进一步膨胀,复溶有大量絮状物。各组冻干后FⅧ活性≥9.3 IU/ml,回收率均较高(≥84.2%);干热后差别明显,其中Ⅲ组(2%白蛋白)FⅧ活性≥9.3 IU/ml,回收率最高(≥90.4%),而Ⅳ组(5%木糖醇)和Ⅵ组(5%木糖醇+1.2%精氨酸)FⅧ活性≤0.94 IU/ml,回收率极低(≤9.8%)。结论在冻干及干热过程中不同冻干保护剂作用差异较大,甘氨酸赋形作用较好,精氨酸对制品中蛋白稳定作用明显,白蛋白对FⅧ活性保护作用最佳;较高浓度的蔗糖不利于冻干过程中水份的去除,木糖醇不适于作为需100℃干热处理的人FⅧ冻干保护剂。
出处 《中国输血杂志》 CAS CSCD 北大核心 2009年第7期556-559,共4页 Chinese Journal of Blood Transfusion
  • 相关文献

参考文献16

  • 1Schwarzinger L, Pabinger I, Kominger C, et al. Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor Ⅷ concentrates. Am J Hematol,2006,24 (3) :241- 245.
  • 2刘占杰,华泽钊.蛋白质药品冷冻干燥过程中变性机理的研究进展[J].中国生化药物杂志,2000,21(5):263-265. 被引量:40
  • 3冉曙光,刘文芳,赵辉.凝血因子Ⅷ浓缩物的制备及安全性和有效性[J].中国输血杂志,2008,21(2):156-159. 被引量:5
  • 4Arrighi S,Rossi R,Borri M G,et al. In vitro and in animal model studies on a double virus-inactivated factor Ⅷ concentrate. Thromb Haemost, 1995,74 (3) : 868-873.
  • 5Dichtelmtlller H, Rudnick D, Breuer B, et al. Improvement of virus safety of a S/D-treated factor Ⅷ concentrate by additional dry heat treatment at 100℃. Biologicals, 1996,24 (2) : 125-130.
  • 6Brodniewicz-Proba T, Beauregard D. Modified glycine precipitation technique for the preparation of factor Ⅷ concentrate high purity and high stability. Vox Sang, 1987,52 (1-2) : 10-14.
  • 7Myers R, Wickerhanser M, Charamella L, et aL Large-scale preparation of highly purified solvent-detrgent treated factor Ⅷ concentrate. Vox Sang, 1991,60 ( 3 ) : 141-147.
  • 8王憬惺,潘文良,杨显富.血浆蛋白制品溶液态加热灭活病毒处理方法:中国,90105776.2[P/OL].1991-09-11[2007-12-20].http://dbpub.enki.net/grid20/Unia/detail.aspx?filename=CN1054373&dbname=SCPD.
  • 9Freudenberg W. Stabilized factor Ⅷ preparations: United States, 5565427[ P/OL]. 1996-10-15[2007-12-22]. http ://www. freepatentsonline. com/5565427. html.
  • 10Arrighi S, Pacenti L, Giuseppina Borrl M. Factor Ⅷ: C concentrate virus Inactivated: progress in purification by using classic chromatographic methods. Vox Sang, 1993,64 ( 1 ) : 13-18.

二级参考文献63

  • 1朱永明,余自强,吴竞生,孙萍.二步法病毒灭活的凝血因子Ⅷ浓缩剂临床疗效及药动学观察[J].临床输血与检验,2001,3(4):11-13. 被引量:1
  • 2王玉琳,曾鸣,王玲,刘晓凡,韩德胜,李根明.病毒活疫苗冻干保护剂筛选研究[J].微生物学免疫学进展,1996,24(1):22-27. 被引量:15
  • 3EMEA警告重组人凝血因子Ⅶ产生抗体的风险[J].中国药物警戒,2006,3(3):187-187. 被引量:2
  • 4Wang W. Lyophilization and development of solid protein pharmaceuticals[J]. Int J Pharm, 2000, 203(1-2): 1-60.
  • 5Chang B S, Randall C S, Lee Y S. Stabilization of lyophilized porcine pancreatic e]astase [J]. Pharm Res,1993, 10(10): 1478-1483.
  • 6Boonyaratanakornkit B B, Park C B, Clark D S. Pressure effects on intra-and intermolecular interactions within proteins[J]. Biochim Biophys Acta, 2002, 1595(1-2): 235-249.
  • 7Costantino H R, Carrasquillo K G, Cordero R A, et al.Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone [J]. J Pharm Sci, 1998, 87: 1412-1420.
  • 8Izutisu K, Yoshioka S, Terao T. Decreased protein-stabilizing effects of cryoprotectants due to crystallization [J].Pharm Res, 1993, 10(8): 1232-1237.
  • 9Wu S L, Leung D, Tretyakov L, et al. The formation and mechanism of multimerization in a freeze-dried peptide[J].Int J Pharm, 2000, 200(1): 1-16.
  • 10Liao Y H, Brown M B, Quader A, et al. Protective mechanism of stabilizing excipients against dehydration in the freeze-drying of proteins[J]. Pharm Res, 2002, 19(12):1854-1861.

共引文献97

同被引文献59

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部